Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France

NCT00812357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 579

Last updated 2011-12-29

No results posted yet for this study

Summary

Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Conditions

Sponsors & Collaborators

Principal Investigators

  • Stephane SCHÜCK, MD, MSc · KAPPA SANTE - Paris - France

  • Michel AUBIER, MD, Professor · CHU Bichat - Service de pneumologie - Paris - France

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-03-31
Completion
2011-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812357 on ClinicalTrials.gov